FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Gooch & Housego plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Broker to Gooch & Housego plc
(d)        Date dealing undertaken: 15th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchases

146,819

1202.5 1202.5

Ordinary shares

Sales

142,377

1205 1202.5

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 16th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Gamma Communications Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Gamma Communications Plc
(d)        Date dealing undertaken: 15th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchases

68,612

1124 1124

Ordinary shares

Sales

68,612

1124 1124

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 16th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken: 15th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchase

1,044,392

281 280.75

Ordinary shares

Sales

912,238

281.25 280.75

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 16th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FOR FURTHER INFORMATION, PLEASE SEE SECTION ENTITLED “IMPORTANT INFORMATION” BELOW.

S-Bank Plc supplements the tender offer document dated 16 July 2026 regarding its voluntary public cash tender offer for all the shares in Oma Savings Bank Plc

OMA SAVINGS BANK PLC     STOCK EXCHANGE RELEASE      16 September 2026 at 10.35 a.m. (EEST)

On 9 July 2026, S-Bank Plc (“S-Bank” or the “Offeror“), announced a voluntary recommended public cash tender offer for all the issued and outstanding shares in Oma Savings Bank Plc (“Oma Savings Bank“) that are not held by Oma Savings Bank or its subsidiaries (the “Tender Offer“). The Offeror has published a tender offer document concerning the Tender Offer on 16 July 2026 and the supplements to the tender offer document, dated 14 August 2026, 31 August 2026 and 7 September 2026 (the tender offer document as supplemented with the aforementioned supplement documents, the “Tender Offer Document“). The offer period to the Tender Offer commenced on 17 July 2026 at 9:30 a.m. (Finnish time) and will expire on 25 September 2026 at 4:00 p.m. (Finnish time), unless the offer period is extended or any extended offer period is discontinued in accordance with the terms and conditions of the Tender Offer (the “Offer Period“).

The Finnish Financial Supervisory Authority has today approved the fourth supplement to the Tender Offer Document (the “Fourth Supplement Document“). The Fourth Supplement Document relates to the stock exchange release published by the Offeror on 15 September 2026, in which the Offeror announced that it has obtained all regulatory approvals necessary for the completion of the Tender Offer.

The Fourth Supplement Document is attached as Appendix 1 to this stock exchange release.

The Finnish language version of the Fourth Supplement Document will be available on the internet at www.s-pankki.fi/ostotarjous, www.omasp.fi/s-pankin-ostotarjous and www.danskebank.fi/omasp as of 16 September 2026. The English language translation of the Fourth Supplement Document will be available on the internet at www.s-pankki.fi/tenderoffer, www.omasp.fi/en/s-banks-tender-offer and www.danskebank.fi/omasp-en as of 16 September 2026. In the event of any discrepancy between the two language versions of the Fourth Supplement Document, the Finnish language version shall prevail.

Additional information:

Oma Savings Bank Plc

Carl Pettersson, Vice Chair of the Board of Directors, interview requests via Chief Communications Officer

Karri Alameri, CEO, interview requests via Chief Communications Officer

Pirjetta Soikkeli, Chief Communications Officer, tel. +358 40 7500 093, pirjetta.soikkeli@omasp.fi

www.omasp.fi

S-Bank Plc

Riikka Laine-Tolonen, CEO, interview requests via communications

Tiina Nurmi, Chief Communications Officer, tel. +358 10 768 1689, tiina.2.nurmi@s-pankki.fi

S-Bank Communications, tel. +358 10 767 9300, viestinta@s-pankki.fi

Information regarding the Tender Offer is available at www.s-pankki.fi/tenderoffer.


ABOUT
 OMA SAVINGS BANK

Oma Savings Bank is a well-capitalised and profitable Finnish bank that serves over 200,000 personal and corporate customers through 48 branches across Finland and digital channels with approximately 600 experts. Oma Savings Bank focuses primarily on retail banking and offers its customers a diverse range of banking services both through its own balance sheet and by intermediating products of its cooperation partners, such as credit, investment and loan protection products. Oma Savings Bank also engages in mortgage banking operations. Oma Savings Bank’s key objective is a first-class customer experience through personal service and easy accessibility in both digital and traditional channels. The Shares of Oma Savings Bank are listed on the regulated market maintained by Nasdaq Helsinki.

ABOUT  S-BANK

S-Bank is a well-capitalised bank and part of the domestic S Group. S-Bank was created as a bank for co-op members with the mission of ensuring that everyone has the possibility of a little more wealth. S-Bank offers its customers banking, financing and wealth management services and engages in mortgage banking operations. At the end of 2025, S-Bank had more than 3.4 million customers, of which 858,000 were active customers. S-Bank’s strategy is to grow the number of active customers and the share of customers who consolidate their banking activities with S-Bank, and to offer superior ease and benefits through a service model that combines digital and personal service. S-Bank employs approximately 1,200 experts.

IMPORTANT INFORMATION

THIS RELEASE MAY NOT BE RELEASED OR OTHERWISE DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW.

THIS RELEASE IS NOT A TENDER OFFER DOCUMENT AND AS SUCH DOES NOT CONSTITUTE AN OFFER OR INVITATION TO MAKE A SALES OFFER. IN PARTICULAR, THIS RELEASE IS NOT AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES DESCRIBED HEREIN, AND IS NOT AN EXTENSION OF THE TENDER OFFER, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA. INVESTORS SHALL ACCEPT THE TENDER OFFER FOR THE SHARES ONLY ON THE BASIS OF THE INFORMATION PROVIDED IN A TENDER OFFER DOCUMENT. OFFERS WILL NOT BE MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE EITHER AN OFFER OR PARTICIPATION THEREIN IS PROHIBITED BY APPLICABLE LAW OR WHERE ANY TENDER OFFER DOCUMENT OR REGISTRATION OR OTHER REQUIREMENTS WOULD APPLY IN ADDITION TO THOSE UNDERTAKEN IN FINLAND.

THE TENDER OFFER IS NOT BEING MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE PROHIBITED BY APPLICABLE LAW AND, WHEN PUBLISHED, THE TENDER OFFER DOCUMENT AND RELATED ACCEPTANCE FORMS WILL NOT AND MAY NOT BE DISTRIBUTED, FORWARDED OR TRANSMITTED INTO OR FROM ANY JURISDICTION WHERE PROHIBITED BY APPLICABLE LAWS OR REGULATIONS. IN PARTICULAR, THE TENDER OFFER IS NOT BEING MADE, DIRECTLY OR INDIRECTLY, IN OR INTO, OR BY USE OF THE POSTAL SERVICE OF, OR BY ANY MEANS OR INSTRUMENTALITY (INCLUDING, WITHOUT LIMITATION, FACSIMILE TRANSMISSION, TELEX, TELEPHONE OR THE INTERNET) OF INTERSTATE OR FOREIGN COMMERCE OF, OR ANY FACILITIES OF A NATIONAL SECURITIES EXCHANGE OF, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA. THE TENDER OFFER CANNOT BE ACCEPTED, DIRECTLY OR INDIRECTLY, BY ANY SUCH USE, MEANS OR INSTRUMENTALITY OR FROM WITHIN, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA AND ANY PURPORTED ACCEPTANCE OF THE TENDER OFFER RESULTING DIRECTLY OR INDIRECTLY FROM A VIOLATION OF THESE RESTRICTIONS WILL BE INVALID.

THIS STOCK EXCHANGE RELEASE HAS BEEN PREPARED IN COMPLIANCE WITH FINNISH LAW, THE RULES OF NASDAQ HELSINKI AND THE HELSINKI TAKEOVER CODE AND THE INFORMATION DISCLOSED MAY NOT BE THE SAME AS THAT WHICH WOULD HAVE BEEN DISCLOSED IF THIS ANNOUNCEMENT HAD BEEN PREPARED IN ACCORDANCE WITH THE LAWS OF JURISDICTIONS OUTSIDE OF FINLAND.

Information for shareholders of Oma Savings Bank in the United States

Shareholders of Oma Savings Bank in the United States are advised that the Shares are not listed on a U.S. securities exchange and that Oma Savings Bank is not subject to the periodic reporting requirements of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act“), and is not required to, and does not, file any reports with the U.S. Securities and Exchange Commission (the “SEC“) thereunder.

The Tender Offer will be made for the issued and outstanding shares of Oma Savings Bank, which is domiciled in Finland, and is subject to Finnish disclosure and procedural requirements. The Tender Offer is made in the United States pursuant to Section 14(e) and Regulation 14E under the Exchange Act, subject to the exemption provided under Rule 14d-1(c) under the Exchange Act, for a “Tier I” tender offer, and otherwise in accordance with the disclosure and procedural requirements of Finnish law, including with respect to the Tender Offer timetable, settlement procedures, withdrawal, waiver of conditions and timing of payments, which are different from those of the United States. In particular, the financial information included in this announcement has been prepared in accordance with applicable accounting standards in Finland, which may not be comparable to the financial statements or financial information of U.S. companies.

You should note that the Offeror’s ability to waive the conditions to the Tender Offer (both during and after the end of the acceptance period) and the shareholders’ ability to withdraw their acceptances, are not the same under a tender offer governed by Finnish law as under a tender offer governed by U.S. law. U.S. shareholders are encouraged to consult with their own advisors regarding the Tender Offer. In particular, the Offeror may waive conditions to the Tender Offer without offering withdrawal rights, to the extent not required by applicable law.

The Tender Offer is made to Oma Savings Bank’s shareholders resident in the United States on the same terms and conditions as those made to all other shareholders of Oma Savings Bank to whom an offer is made. Any informational documents, including this announcement, are being disseminated to U.S. shareholders on a basis comparable to the method that such documents are provided to Oma Savings Bank’s other shareholders.

To the extent permissible under applicable law or regulations, the Offeror and its affiliates or its brokers and its brokers’ affiliates (acting as agents for the Offeror or its affiliates, as applicable) may from time to time after the date of this stock exchange release and during the pendency of the Tender Offer, and other than pursuant to the Tender Offer, directly or indirectly purchase or arrange to purchase Shares or any securities that are convertible into, exchangeable for or exercisable for Shares. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. To the extent information about such purchases or arrangements to purchase is made public in Finland, such information will be disclosed by means of a press release or other means reasonably calculated to inform U.S. shareholders of Oma Savings Bank of such information. In addition, the financial advisers to the Offeror may also engage in ordinary course trading activities in securities of Oma Savings Bank, which may include purchases or arrangements to purchase such securities. To the extent required in Finland, any information about such purchases will be made public in Finland in the manner required by Finnish law.

Neither the SEC nor any U.S. state securities commission has approved or disapproved the Tender Offer, passed upon the merits or fairness of the Tender Offer, or passed any comment upon the adequacy, accuracy or completeness of the disclosure in relation to the Tender Offer. Any representation to the contrary is a criminal offence in the United States.

The receipt of cash pursuant to the Tender Offer by a U.S. holder of Shares may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each holder of Shares is urged to consult its independent professional advisers immediately regarding the tax and other consequences of accepting the Tender Offer.

To the extent the Tender Offer is subject to U.S. securities laws, those laws only apply to U.S. holders of Shares and will not give rise to claims on the part of any other person. It may be difficult for Oma Savings Bank’s shareholders to enforce their rights and any claims they may have arising under the U.S. federal securities laws, since the Offeror and Oma Savings Bank are located in non-U.S. jurisdictions and some or all of their respective officers and directors may be residents of non-U.S. jurisdictions. Oma Savings Bank shareholders may not be able to sue the Offeror or Oma Savings Bank or their respective officers or directors in a non-U.S. court for violations of the U.S. federal securities laws. It may be difficult to compel the Offeror and Oma Savings Bank and their respective affiliates to subject themselves to a U.S. court’s judgment.

Forward-looking statements

This release contains statements that, to the extent they are not historical facts, constitute “forward-looking statements”. Forward-looking statements include statements concerning plans, expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position, future operations and development, business strategy and the trends in the industries and the political and legal environment and other information that is not historical information. In some instances, they can be identified by the use of forward-looking terminology, including the terms “believes”, “intends”, “may”, “will” or “should” or, in each case, their negative or variations on comparable terminology. By their very nature, forward-looking statements involve inherent risks, uncertainties and assumptions, both general and specific, and risks exist that the predictions, forecasts, projections and other forward-looking statements will not be achieved. Given these risks, uncertainties and assumptions, investors are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements contained herein speak only as at the date of this release.

Disclaimer

PricewaterhouseCoopers Oy is acting as financial adviser to the Offeror and no-one else in connection with this announcement. Neither PricewaterhouseCoopers Oy nor its affiliates, nor their respective partners, directors, officers, employees or agents are responsible to anyone other than the Offeror for providing the protections afforded to clients of PricewaterhouseCoopers Oy or for providing advice in connection with any matters referred to in this announcement.

Danske Bank A/S is authorised under Danish banking law. It is subject to supervision by the Danish Financial Supervisory Authority. Danske Bank A/S is a private, limited liability company incorporated in Denmark with its head office in Copenhagen where it is registered in the Danish Commercial Register under number 61126228.

Danske Bank A/S (acting via its Finland Branch) is acting as arranger for the benefit of the Offeror and no other person in connection with these materials or their contents. Danske Bank A/S will not be responsible to any person other than the Offeror for providing any of the protections afforded to clients of Danske Bank A/S, nor for providing any advice in relation to any matter referred to in these materials. Without limiting a person’s liability for fraud, Danske Bank A/S, nor any of its affiliates nor any of its respective directors, officers, representatives, employees, advisers or agents shall have any liability to any other person (including, without limitation, any recipient) in connection with the Tender Offer.

EY Advisory Oy is acting exclusively for Oma Savings Bank Plc and no one else in connection with the Tender Offer and the matters set out in this announcement. Neither EY Advisory Oy nor its affiliates, nor their respective partners, directors, officers, employees or agents are responsible to anyone other than Oma Savings Bank for providing the protections afforded to clients of EY Advisory Oy, or for giving advice in connection with the Tender Offer or any matter or arrangement referred to in this announcement.

Appendix 1: Fourth Supplement Document

Attachment

VANCOUVER, BRITISH COLUMBIA, Sept. 16, 2026 (GLOBE NEWSWIRE) — HI-VIEW RESOURCES INC. (“Hi-View” or the “Company”) (CSE: GXLD; OTCQB: GXLDF; FSE: B630) announces that it has acquired the Jim Property in the Toodoggone Gold & Copper District of northern British Columbia. The Property is contiguous to Thesis Gold & Silver’s land package and lies near Evergold Corp.’s Golden Lion project.

R Nick Horsley, Chief Executive Officer of Hi-View, commented: “The Jim Property acquisition further adds to our existing land position in the Toodoggone district. The property is surrounded by Thesis Gold & Silver’s northern land package. With a gossanous zone visible at surface, we believe this could indicate hidden sulphide mineralization at depth, possibly associated with a copper porphyry system. We see this as a target worth following up on.”

Figure 1. Jim Property with gossanous zone highlighted.
Click here to view image

The Property hosts the historic ‘JM’ showing, first documented in 1988 and sits adjacent to Thesis Gold & Silver’s land package and near Evergold’s Golden Lion project.

Malachite staining with associated chalcopyrite, was noted throughout the area, lining fracture planes and associated with quartz and calcite stringers within narrow shears. The combination of copper sulphides and oxides with gold and silver values, localized in fractures, shears, and quartz-calcite veining, suggests an epithermal hydrothermal system with stronger mineralization potentially concealed beneath the gossanous zone. Historically, the area has only been prospected so further mapping and analyses are warranted to follow up on. We see this as an opportunity to advance an epithermal target in a district that already hosts the Kemess, Aurora, Lawyers, and Baker deposits.

Terms of the Agreement

The Company has acquired 100% interest in the Property from an arm’s length vendor by issuing 100,000 common shares of the Company, making a $5,000 cash payment, and granting the vendor a 2% net smelter returns royalty (NSR) on the Property, of which the Company has the right to buy back 1% for $1,000,000.

Qualified Person’s Statement

The technical content of this news release has been reviewed and approved by Nader Mostaghimi, P.Geo., The technical content of this news release has been reviewed and approved by Nader Mostaghimi, M.Sc., P.Geo. (EGBC #53441), Vice President of Exploration for the Company and a Qualified Person as defined by National Instrument 43-101.

About Hi-View Resources Inc.

Hi-View Resources Inc., a publicly listed mineral exploration company on the Canadian Securities Exchange, is advancing a portfolio of gold, silver, and copper assets in the Toodoggone region of northern British Columbia. The Company’s 100% owned and optioned projects cover more than 27,910 hectares and include the flagship Golden Stranger Project, the Lawyers claims, and the Borealis Project — all designated as high-priority targets. Additional properties under option include Saunders, Black Pearl, Oxide Summit, Nub, Ursus, Garnet, and Harmon Peak. The company also has an additional 1,300 hectares currently under mineral claim application. For more information, please visit Hi-View’s website or review the Company’s filings on SEDAR+ (www.sedarplus.ca).

On Behalf of the Board of Directors,
“R. Nick Horsley”
R. Nick Horsley, CEO

For further information, please contact:

Hi-View Resources Inc.
R. Nick Horsley – CEO
Email: info@hiviewresources.com
Telephone: (604) 343-4337
Website: www.hiviewgold.com

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.  Forward-looking statements in this news release includes statements related to the Incentive Program and the anticipated use of proceed therefrom. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release. 

WE SEEK SAFE HARBOUR

KKR joins Apollo as a minority participant

NEW YORK and LEVERKUSEN, Germany, Sept. 16, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Apollo-managed funds and affiliates (“Apollo”) have successfully closed a €3 billion capital solution for Bayer, previously announced on July 10. KKR has joined Apollo as a significant minority participant in the investment.

Under the transaction, Apollo, together with KKR, have invested equity capital into a newly established entity holding Bayer’s long-acting reversible contraceptives (LARC) business. Bayer retains a majority stake in the entity and continues to exercise full operational control over the business; there are no changes to the LARC strategy as a result of the investment.

Apollo Partner Jamshid Ehsani said, “We are proud to serve as a capital partner to Bayer, originating and leading a multi-billion-euro capital solution tailored to their needs. Bayer, a global life sciences leader and iconic German company, represents the types of large, blue-chip companies we serve through our High Grade Capital Solutions business.”

Ehsani added, “Apollo has committed to deploying more than $100 billion in Germany over the coming decade, and Bayer exemplifies the kind of strategic, long-term partnership we seek to build with the country’s most important companies.”

Centerview Partners served as financial advisor to the Apollo Funds. Latham & Watkins LLP, Paul, Weiss, Rifkind, Wharton & Garrison LLP, and NautaDutilh N.V. are legal counsel to the Apollo Funds.

About Apollo
Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees and the communities we impact, to expand opportunity and achieve positive outcomes. As of June 30, 2026, Apollo had approximately $1.05 trillion of assets under management. To learn more, please visit www.apollo.com.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Contacts:

Apollo

Noah Gunn
Global Head of Investor Relations
(212) 822-0540
IR@apollo.com

Joanna Rose
Global Head of Corporate Communications
(212) 822-0491
Communications@apollo.com / EuropeanMedia@apollo.com

KKR

Julia Leeger
+44 20 7839 9800
media@kkr.com

Bayer

Investor Relations: ir@bayer.com
Corporate Media Relations: christian.hartel@bayer.com

LONDON, Sept. 16, 2026 (GLOBE NEWSWIRE) — The Lake District has emerged as Britain’s capital of romantic stays, according to new data from leading travel search engine KAYAK.

KAYAK’s search data also points to growing interest for more indulgent escapes, with luxury and romantic stays seeing the biggest gains in accommodation searches, up 13% and 7% year-on-year respectively.

With new adaptations of Wuthering Heights, Sense and Sensibility and Pride and Prejudice putting literary romance in the spotlight in 2026, KAYAK analysed bookable UK accommodation to identify the destinations with the highest proportion of properties categorised as romantic.

Windermere topped the ranking, with more than one in three properties (36%) meeting the criteria. Keswick placed second at 35% and is also among the fastest-rising destinations in KAYAK searches. Harrogate ranked third, followed by Cheltenham and Penzance.

Britain’s most romantic getaway destinations

  1. Windermere (36%)
  2. Keswick (35%)
  3. Harrogate (33%)
  4. Cheltenham (32%)
  5. Penzance (32%)
  6. Stratford-upon-Avon (31%)
  7. Sidmouth (30%)
  8. Ambleside (29%)
  9. Canterbury (29%)
  10. Leeds (29%)

Rachel Mumford, KAYAK UK travel expert, said, “There’s something undeniably romantic in seeing a place that reminds you of a great British love story.

“And there seem to be a clear trend in staying somewhere that’s fuelled by nostalgia and a growing fascination with the ‘olden days’.

“From lakeside walks and historic towns to cosy hotels and dramatic coastlines, these destinations have many of the ingredients people associate with a classic. And with Autumn’s arrival – it’s the perfect time to swap the city break for something a little slower and more atmospheric.”

For an autumn escape, KAYAK recommends these top 5 stays in the top 5 most romantic towns:

About KAYAK  

KAYAK, part of Booking Holdings (NASDAQ: BKNG), is a leading travel search engine. With billions of queries across our platforms, we help people find their perfect flight, stay, rental car and vacation package. Trusted by millions of travellers, the KAYAK app makes travel planning seamless on iOS and Android, and we also support business travellers with our corporate travel solution.  

CONTACT: For more information and imagery, please contact kayak@ready10.media

Press Release
Nokia Defense and C3IA partner to accelerate digital transformation across UK defense operations

  • Partnership combines Nokia Defense’s advanced connectivity with C3IA’s systems engineering, capability integration and security services expertise to support UK defense modernization.
  • Focuses on delivering resilient multi-domain capabilities spanning tactical communications, C2, sensing, autonomous systems and edge computing.
  • Builds on Nokia Defense and C3IA’s participation in the UK MOD TacSys framework to enhance tactical communications and interoperability.

16 September 2026
Espoo, Finland – At the 2026 DVD (Defence Vehicle Dynamics) event, Nokia Defense and C3IA, a UK specialist in systems engineering, capability integration and security services, announced the signing of a memorandum of understanding (MoU) to strengthen collaboration and support the digital transformation of UK Defense. The partnership combines Nokia’s expertise in advanced connectivity with C3IA’s engineering, capability integration, support and security services to help deliver next-generation defense capabilities for modern, multi-domain operations.

Together, the companies will deliver resilient communications, secure information sharing and network interoperability across land, air, maritime, cyber and space domains. The collaboration also builds on Nokia Defense and C3IA’s participation in the UK Ministry of Defence (MOD) Tactical Communication Systems (TacSys) framework, providing access to Nokia’s full connectivity portfolio from headquarters to the tactical edge.

Modern military operations increasingly depend on the ability to securely connect people, platforms, sensors and data across multiple domains. Under the agreement, Nokia Defense and C3IA will co-develop solutions across tactical and operational communications, private 4G and 5G, situational awareness, command and control (C2), sensing, autonomous systems and edge computing. The collaboration will focus on translating advanced communications technologies into practical, integrated capabilities that address real operational requirements for the defense sector.

“Through this collaboration with C3IA, we are combining resilient, mission-critical connectivity with expertise in defense systems engineering and support services to help turn technology into operational capability and advance tactical communications and interoperability across future UK defense programs,” said Mikko Viitaniemi, Vice President and Head of Nokia Defense.

“Delivering defense capability at pace requires more than technology alone. It requires the right combination of secure communications, sector expertise and systems integration. Our partnership with Nokia enables the rapid deployment of innovative capabilities that can deliver real operational value on the battlefield. Ultimately, our shared goal is to connect the battlespace, strengthen national security, and help equip the MOD for the future,” said Steve Brown, Managing Director, C3IA.

Nokia Defense and C3IA participate in the UK Government’s TacSys framework (RM6393) in Lot 1 (Services) and Lot 3 (Components), giving the UK MOD and other public sector organizations the ability to procure Nokia’s connectivity portfolio to support future tactical communications requirements.

Nokia Defense provides secure, intelligent connectivity for defense in the AI era. Built on Nokia’s global leadership across fixed, mobile, and transport networks, it delivers resilient, mission-ready communications solutions that strengthen national security and support critical operations worldwide.

Multimedia, technical information and related news
Web Page: www.nokia.com/defense-communications
Web Page: www.c3ia.co.uk

About Nokia
Nokia is the world’s leading provider of network technology and enables a new era of artificial intelligence. We are developing the networks of the future that connect people, devices and intelligence. Our network solutions span fixed and mobile networks, as well as IP, optical, core, and data center networks. Our secure, AI-native network infrastructure enables the application and utilization of AI on a global scale.

About C3IA
C3IA provides technical and security services across both public and private sectors. Specialising in systems engineering, ICT, information assurance, and NCSC-assured cyber services, C3IA plays a pivotal role in supporting the delivery of critical defence programmes. C3IA is dedicated to building long-lasting relationships with our clients, partners and community, delivering exceptional value through our commitment to quality and collaboration.

Media inquiries
Nokia Press Office
Email: Press.Services@nokia.com

Follow us on social media
LinkedIn X Instagram Facebook YouTube

  • New data will highlight the breadth of semaglutide evidence across the cardiometabolic spectrum, including obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease, and new data on Wegovy® pill, Wegovy® 7.2 mg and Ozempic® 2.0 mg
  • Real-world evidence from the OCTANE study will provide insights into Wegovy® pill use in adults with overweight or obesity, including weight outcomes, treatment switching and patient-reported outcomes
  • CagriSema and amylin-based pipeline data will provide new insights into appetite regulation, eating behaviour, food noise, body composition and bone health (bone remodelling mechanisms). The data will advance our understanding of the underlying biology of obesity and type 2 diabetes and inform next-generation cardiometabolic innovation.

Bagsværd, Denmark, 16 September 2026 – Novo Nordisk today announced that new data from its cardiometabolic pipeline and portfolio will be presented at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026 in Milan, Italy, from 28 September to 2 October. The data to be presented at EASD will bring new scientific insights shared across obesity, type 2 diabetes, cardiovascular, kidney and liver-related outcomes. Together, the presentations reflect Novo’s continued focus on advancing understanding and treatment of interconnected cardiometabolic diseases to help many more patients.

A total of 44 abstracts will be presented, including data across semaglutide, CagriSema, and zenagamtide. Key presentations will include real-world evidence on Wegovy® pill and CagriSema data exploring appetite regulation, eating behaviour and brain responses to food cues using fMRI (functional Magnetic Resonance Imaging; a non-invasive brain scan that shows which areas of the brain are active during specific tasks or while at rest), and CagriSema data in type 2 diabetes looking at body composition, organ-level fat and bone remodelling mechanisms. Additional presentations include data on semaglutide addressing excess liver fat in people with obesity, and real-world evidence comparing major adverse cardiovascular events in adults with type 2 diabetes escalating to semaglutide 2.0 mg versus switching to tirzepatide.

“At EASD 2026 we are sharing the breadth and progression of our cardiometabolic portfolio and pipeline, including key insights that show how our science could make a difference in the everyday lives of people living with obesity, diabetes and related diseases,” said Martin Holst Lange, executive vice president of Research & Development and chief scientific officer at Novo. “We are presenting real-world data on Wegovy® pill, new insights into the broader benefits of semaglutide across Wegovy® and Ozempic®, and CagriSema research exploring food noise, brain responses and body composition. Together, these findings have the potential to shape the next generation of cardiometabolic care and reflect our ambition to develop treatments that can help us work towards more meaningful outcomes for patients.”

Media are invited to listen to an International Press Briefing on Wednesday, 30 September 2026, during EASD in Milan. The event will be accessible via a webcast on the Novo website, sign up via this link: Novo Nordisk: EASD International Press Briefing, 30 September 2026 (Virtual only)

Summary of presentations
Accepted data at the 62nd Annual Meeting of the EASD include the following oral presentations and short oral discussions. Accepted abstracts include preliminary data that may be subject to change in the final published manuscripts. Dates and times of the presentations can be found on the EASD website.

Select Novo abstracts to be presented at EASD’s 2026 Scientific Sessions:

EASD Scientific symposium:

  • REIMAGINE 1,2 and 3 Trial: Trial designs, key results and clinical perspectives: Scientific Session presentation (S21: Amylin in diabetes and obesity: What’s new?) – Wednesday 30 September; 16:30 – 17:30 CEST

Novo oral presentations and short oral discussions:

CagriSema (diabetes and obesity)

  • Efficacy of CagriSema on body composition in participants with early type 2 diabetes: REIMAGINE 1. Oral presentation (LBA 11) – Tuesday 29 September; 14:45–16:15 CEST
  • Effect of CagriSema on achievement of composite HbA1c and weight reduction targets in participants with type 2 diabetes: REIMAGINE 1. Oral presentation (LBA 12) – Tuesday 29 September; 14:45–16:15 CEST
  • fMRI – Effects of CagriSema on appetite, eating behaviour and food cue reactivity using functional MRI in adults with overweight or obesity. Oral presentation (122) – Wednesday 30 September; 14:30–16:00 CEST

Cagrilintide

  • Impact of cagrilintide 2.4 mg on physical function: post-hoc patient-reported outcomes from REDEFINE 1. Short oral discussion (593) – Tuesday 29 September; 12:00–13:00 CEST

Zenagamtide (diabetes)

  • Zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist: phase 2b results in type 2 diabetes. Oral presentation (13) – Wednesday 30 September; 9:45–11:15 CEST

Wegovy® (injection and tablets)

  • OCTANE RWE US study: 3-month real-world weight outcomes among patients with overweight or obesity after switching from injectable semaglutide or tirzepatide to oral semaglutide for weight management. Short oral discussion (LBA 59) – Wednesday 30 September; 11:45–12:45 CEST
  • Effect of semaglutide on liver measures and indices: pooled analysis from the STEP UP studies. Short oral discussion (529) – Thursday 1 October; 12:45–13:45 CEST

Ozempic®

  • COMPETE SWITCH CV: Major adverse cardiovascular events in adults with type 2 diabetes escalating to semaglutide 2.0 mg vs switching to tirzepatide: Short oral discussion (LBA 44) – Tuesday 29 September; 12:00–13:00 CEST
  • Sema 2.0-7.2 bridging: Pharmacometric modelling of escalating to subcutaneous semaglutide once-weekly 7.2 mg from 2.0 mg in a STEP UP T2D population: predicting weight reduction and gastrointestinal tolerability. Short oral discussion (824) – Tuesday 29 September; 13:15–14:15 CEST
  • Post-hoc analysis from SUSTAIN FORTE: Achievement of HbA1c, body weight loss and hypoglycaemia composite endpoints with once-weekly semaglutide 2.0 mg versus 1.0 mg in T2D. Short oral discussion (828) – Tuesday 29 September; 13:15–14:15 CEST
  • SUSTAIN OPTIMIZE CGM: Continuous glucose monitoring outcomes with once-weekly s.c. semaglutide 2.0 mg added to dose-reduced basal insulin vs dose-titrated basal insulin in adults with type 2 diabetes: Oral presentation (14) – Tuesday 29 September; 10:00–11:30 CEST
  • FLOW mediation analysis: Evidence from mediation analysis of 72 pre-specified cardio-kidney-metabolic proteins: Oral presentation (LBA 30) – Thursday 1 October; 15:30–17:00 CEST
  • FLOW trial plasma proteomics: identifies prognostic signatures and pharmacodynamic pathway modulation by semaglutide. Oral presentation (LBA 28) – Thursday 1 October; 15:30–17:00 CEST
  • Semaglutide RWE in China T2D (SPOTLIGHT): Semaglutide reduces the risk of cardiovascular and renal events in Chinese type 2 diabetes patients – a real-world retrospective database study. Short oral discussion (Event A, 733) – Tuesday 29 September; 12:00-13:00
  • SPOTLIGHT primary prevention: Semaglutide reduces cardiovascular event risk in the primary prevention setting among Chinese patients with type 2 diabetes: a real-world retrospective cohort study. Short oral discussion (Event A, LBA 40) – Tuesday 29 September; 12:00-13:00
  • SPOTLIGHT combination therapy: Semaglutide in combination use with SGLT2i reduces cardiovascular events compared to SGLT2i alone use in Chinese patients with type 2 diabetes. Short oral discussion (Event A, LBA 42) – Tuesday 29 September; 12:00-13:00

UBT251 (diabetes and obesity):

  • UBT251 (obesity), a triple hormone receptor agonist in adults with overweight or obesity: a multicenter, double-blind, placebo-controlled, randomized, phase 2 trial. Short oral discussion (Event D, 797) – Wednesday 30 September; 13:00–14:00 CEST
  • UBT251 (diabetes), a triple GLP-1, GIP, and GCG receptor agonist in patients with type 2 diabetes: a multicenter, double-blind, placebo- and active-controlled, randomised, phase II trial. Oral presentation (124) – Wednesday 30 September; 14:30–16:00 CEST

Insulin Icodec

  • ONWARDS 10 CGM-based metrics: Continuous glucose monitoring-based metrics in adults switching to once-weekly icodec without an initial one-time additional dose vs once-daily glargine U100. Post hoc analysis of ONWARDS 10. Short Oral discussion (Event F, 860) – Thursday 1 October; 14:00–15:00 CEST

IcoSema

  • COMBINE 4 BL BMI: Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs glargine U100 in T2D by baseline BMI: COMBINE 4. Short oral discussion (854) – Thursday 1 October; 12:45–13:45 CEST
  • COMBINE 4 BL HbA1c: Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs glargine U100 in T2D by baseline HbA1c: COMBINE 4. Short oral discussion (853) – Thursday 1 October; 12:45–13:45 CEST

About semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of the naturally occurring hormone GLP-1, which regulates blood sugar and body weight. Semaglutide has been tested in several robust clinical development programmes and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases. Semaglutide is marketed under the brand names Wegovy® (injection or tablet), Ozempic® (injection or tablet) and Rybelsus® (tablet).

About CagriSema
CagriSema is being investigated by Novo as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.

About Fatty liver disease
Fatty liver disease – also known as MASH (metabolic dysfunction-associated steatohepatitis) – is a common condition in which excess fat builds up in the liver. Over time, this can cause inflammation and liver damage, especially in people with obesity, type 2 diabetes or other metabolic health conditions. The disease can range from mild fat buildup to more serious forms that may lead to scarring and reduced liver function.

About zenagamtide
Zenagamtide, formerly known as amycretin, is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo to provide a treatment for adults with overweight or obesity (AMAZE programme) and as a treatment for adults with type 2 diabetes (AMBITION programme). Zenagamtide is under investigation for oral and subcutaneous administration.

About type 2 diabetes
Type 2 diabetes is a chronic condition that affects how the body processes blood sugar (glucose) for energy. 589 million adults (20-79 years) are living with diabetes – 1 in 9. This number is predicted to rise to 853 million by 2050. Diabetes was responsible for 3.4 million deaths in 2024 – 1 every 9 seconds.

About obesity
Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. Obesity is influenced by a variety of factors, including genetics, social determinants of health and the environment.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Nordisk Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com

Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com

Novo Nordisk Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com

Sina Meyer
+45 3079 6656
azey@novonordisk.com

Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com

 
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com

Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com

Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com

Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

Attachment

September 16, 2026
News Release

First Patient In – BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.

COPENHAGEN, DENMARK, September 16 , 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced the enrollment of the first patient as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to expand ProNephro AKI (NGAL) to the adult population. The ProNephro AKI U.S. Adult Urine NGAL Validation Study is designed to validate the clinical performance of ProNephro AKI (NGAL) for risk assessment of moderate to severe Acute Kidney Injury (AKI) in adult patients admitted to the Intensive Care Unit (ICU). The study follows BioPorto’s recently completed adult AKI cut-off study and represents the next phase of clinical evaluation for a potential adult indication in the United States.

CEO Carsten Buhl commented: “Today’s first patient enrollment marks another major milestone in BioPorto’s strategy to expand ProNephro AKI into the U.S. adult market. Following the successful completion of the AKI cut-off study, we are now advancing into the validation phase with a study designed to enroll approximately 900 patients across leading U.S. hospitals. Together with ProPharma, our clinical research partner from the preceding study, we are taking the critical steps toward generating the clinical evidence needed to support an adult indication in the United States.”

First patient enrollment for the ProNephro AKIU.S. Adult Urine NGAL Validation Study

The first patient in the ProNephro AKI U.S. Adult Urine NGAL Validation Study has been enrolled at Massachusetts General Hospital. The study is expected to enroll approximately 900 patients across multiple U.S. clinical sites, creating a broad and representative clinical dataset to support the expansion of ProNephro AKI (NGAL) to adult patients.

BioPorto Continues with ProPharma as Clinical Research Organization

BioPorto will continue with ProPharma as the Clinical Research Organization in the study, following its involvement in the preceding AKI cut-off study. ProPharma also assisted BioPorto as the Clinical Research Organization in the ProNephro AKI U.S. Adult Urine NGAL cut-off Study.

ProNephro AKI (NGAL) is currently cleared by the U.S. Food and Drug Administration (FDA) for patients 3 months through 21 years of age. The ProNephro AK U.S. Adult Urine NGAL Validation Study is intended to support BioPorto’s clinical and regulatory pathway toward a potential adult indication in the United States.

To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/.

Investor Relations contacts

Klaus Juhl Wulff, BioPorto A/S, investor@bioporto.com, C: +45 25 63 39 90

Forward looking statement disclaimer

Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company’s expectations, intentions and projections regarding its future performance including the Company’s Guidance for 2026; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company’s ability to successfully market both new and existing products. These forward-looking statements, which may use words such as “aim”, “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company’s business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto’s success are more fully disclosed in BioPorto’s periodic financial filings, including its Annual Report for 2025, particularly under the heading “Risk Factors”.

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.